{"entity":{"id":"nct06421935","kind":"trial","name":"M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)","aka":[],"tldr":"This study tests a PARP inhibitor; the registry reports that it is active not recruiting.","summary":"The registry lists NCT06421935 as active not recruiting, last updated 2026-09-09. Enrolment is 60 actual participants. Interventions: M9466, Tuvusertib, Abiraterone acetate, Prednisone/Prednisolone. Primary measures include Module 1 Part A1 and Part A2: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Treatment-related AEs (TRAEs); Module 1 Part A1 and Part A2: Number of Participants with Dose Limiting Toxicity (DLT)-like events. No results are posted in the registry; this does not exclude separate publications.","status":"active","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06421935","url":"https://clinicaltrials.gov/study/NCT06421935"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["parp"],"drugs":["hrs-1167"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06421935","phase":"1","setting":"An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 Alone or in Combination in Participants With Advanced Solid Tumors","sponsor":"EMD Serono Research & Development Institute, Inc.","started":"2024-08-07","startedType":"actual","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06421935/","neighbours":{"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"hrs-1167","kind":"drug","name":"HRS-1167","route":"/drugs/hrs-1167/"}]}}